333 related articles for article (PubMed ID: 20219697)
1. Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.
Greineisen WE; Turner H
Int Immunopharmacol; 2010 May; 10(5):547-55. PubMed ID: 20219697
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoids for the treatment of inflammation.
Ashton JC
Curr Opin Investig Drugs; 2007 May; 8(5):373-84. PubMed ID: 17520866
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoids as novel anti-inflammatory drugs.
Nagarkatti P; Pandey R; Rieder SA; Hegde VL; Nagarkatti M
Future Med Chem; 2009 Oct; 1(7):1333-49. PubMed ID: 20191092
[TBL] [Abstract][Full Text] [Related]
6. Basic neuroanatomy and neuropharmacology of cannabinoids.
Breivogel CS; Sim-Selley LJ
Int Rev Psychiatry; 2009 Apr; 21(2):113-21. PubMed ID: 19367505
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
Svízenská I; Dubový P; Sulcová A
Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of cannabinoids.
Grotenhermen F
Neuro Endocrinol Lett; 2004; 25(1-2):14-23. PubMed ID: 15159677
[TBL] [Abstract][Full Text] [Related]
9. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.
Gutierrez T; Farthing JN; Zvonok AM; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Jan; 150(2):153-63. PubMed ID: 17160008
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.
Borrelli F; Fasolino I; Romano B; Capasso R; Maiello F; Coppola D; Orlando P; Battista G; Pagano E; Di Marzo V; Izzo AA
Biochem Pharmacol; 2013 May; 85(9):1306-16. PubMed ID: 23415610
[TBL] [Abstract][Full Text] [Related]
11. Plant cannabinoids: a neglected pharmacological treasure trove.
Mechoulam R
Br J Pharmacol; 2005 Dec; 146(7):913-5. PubMed ID: 16205721
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
Wilkinson JD; Williamson EM
J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
[TBL] [Abstract][Full Text] [Related]
13. Effects of Cannabinoids on T-cell Function and Resistance to Infection.
Eisenstein TK; Meissler JJ
J Neuroimmune Pharmacol; 2015 Jun; 10(2):204-16. PubMed ID: 25876735
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
15. Modulatory effects of cannabinoids on brain neurotransmission.
Cohen K; Weizman A; Weinstein A
Eur J Neurosci; 2019 Aug; 50(3):2322-2345. PubMed ID: 30882962
[TBL] [Abstract][Full Text] [Related]
16. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.
Mendizábal VE; Adler-Graschinsky E
Br J Pharmacol; 2007 Jun; 151(4):427-40. PubMed ID: 17450170
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.
Tambaro S; Casu MA; Mastinu A; Lazzari P
Eur J Pharmacol; 2014 Apr; 729():67-74. PubMed ID: 24561047
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming.
Angelina A; Pérez-Diego M; López-Abente J; Rückert B; Nombela I; Akdis M; Martín-Fontecha M; Akdis C; Palomares O
Mucosal Immunol; 2022 Jan; 15(1):96-108. PubMed ID: 34548620
[TBL] [Abstract][Full Text] [Related]
20. Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis.
Pandey R; Hegde VL; Singh NP; Hofseth L; Singh U; Ray S; Nagarkatti M; Nagarkatti PS
Vitam Horm; 2009; 81():487-504. PubMed ID: 19647124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
